Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study

ZHOU Jian-ya; ZHOU Jian-ying

doi:10.12019/j.issn.1671-5144.2021.04.004

ZHOU Jian-ya, ZHOU Jian-ying. Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004

Citation:

ZHOU Jian-ya, ZHOU Jian-ying. Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004

Citation:

ZHOU Jian-ya, ZHOU Jian-ying. Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004

Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study

Graphical Abstract

Abstract

FullText(HTML)

References (11)

Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study

Catalog

Export File

Citation

Format

Content